Rosiglitazone and Hepatic Failure

Letters18 January 2000Rosiglitazone and Hepatic FailureJeffrey Freid, MD, Daniel Everitt, MD, and Jerome Boscia, MDJeffrey Freid, MDSmithKline Beecham; Philadelphia, PA 19101 (Freid)SmithKline Beecham; Philadelphia, PA 19101 (Everitt)SmithKline Beecham; Philadelphia, PA 19101 (Boscia)Search for more papers by this author, Daniel Everitt, MDSmithKline Beecham; Philadelphia, PA 19101 (Freid)SmithKline Beecham; Philadelphia, PA 19101 (Everitt)SmithKline Beecham; Philadelphia, PA 19101 (Boscia)Search for more papers by this author, and Jerome Boscia, MDSmithKline Beecham; Philadelphia, PA 19101 (Freid)SmithKline Beecham; Philadelphia, PA 19101 (Everitt)SmithKline Beecham; Philadelphia, PA 19101 (Boscia)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-132-2-200001180-00015 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:In this issue, Forman and colleagues (1) report on a patient who developed severe liver dysfunction while receiving rosiglitazone. Although we have not had the opportunity to review the manuscript of this case report in advance of publication, we would like to point out some important facts about the case. Our company was informed of this patient's clinical status at the time the events occurred. We immediately requested, and were able to obtain, entire medical records from both the community hospital where the patient initially presented and from the university hospital where the patient was transferred. These ...References1. Forman LM, Simmons DA, Diamond RH. Hepatic failure in a patient taking rosiglitazone. Ann Intern Med. 2000;132:118-21. LinkGoogle Scholar2. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med. 1998;338:916-7. CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Jeffrey Freid, MD; Daniel Everitt, MD; Jerome Boscia, MDAffiliations: SmithKline Beecham; Philadelphia, PA 19101 (Freid)SmithKline Beecham; Philadelphia, PA 19101 (Everitt)SmithKline Beecham; Philadelphia, PA 19101 (Boscia) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoHepatic Failure in a Patient Taking Rosiglitazone Lisa M. Forman , David A. Simmons , and Robert H. Diamond Rosiglitazone and Liver Failure William L. Isley and Julie C. Oki Rosiglitazone and Liver Failure Lisa M. Forman and Robert H. Diamond Isolated Elevation of Alkaline Phosphatase Level Associated with Rosiglitazone David M. Hachey , Michael P. O'Neil , and Rex W. Force Metrics Cited byEffects of rosiglitazone on growth and skeletal muscle glucose metabolism of GIFT tilapia based on PI3K/Akt signaling pathwayRosiglitazone promotes glucose metabolism of GIFT tilapia based on the PI3K/Akt signaling pathwayNonsteroidal Antiinflammatory Drugs and Leukotriene Receptor AntagonistsExamining the safety of PPAR agonists – current trends and future prospectsHepatic injury due to drugs, herbal compounds, chemicals and toxinsTroglitazoneLiver Disease Caused by DrugsCausality Assessment of Drug-Induced Hepatotoxicity: Promises and PitfallsDephosphorylation of ribosomal protein P0 in response to troglitazone-induced cytotoxicity‘Hy's law,’ the ‘Rezulin Rule,’ and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspectiveCombination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitusSecond-Generation Thiazolidinediones and HepatotoxicityHepatotoxicity of thiazolidinedionesManagement of Rosiglitazone-Induced Edema: Two Case Reports and a Review of the LiteratureEffects of Pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: A retrospective review of randomly selected medical recordsRosiglitazoneA Review of Rosiglitazone in Type 2 Diabetes MellitusOral agents for the treatment of type 2 diabetes mellitus: Pharmacology, toxicity, and treatmentDrug-induced liver diseasePolycystic Ovary Syndrome and Insulin Resistance: New Approaches to Management, including ExerciseFactors Associated with the Risk of Liver Enzyme Elevation in Patients with Type 2 Diabetes Treated with a ThiazolidinedioneFailure to Develop Hepatic Injury From Rosiglitazone in a Patient With a History of Troglitazone-Induced HepatitisDisorders of Glucose Metabolism in Patients Infected with Human Immunodeficiency VirusPathophysiology and Pharmacological Treatment of Insulin Resistance*Isolated Elevation of Alkaline Phosphatase Level Associated with RosiglitazoneDavid M. Hachey, PharmD, Michael P. O'Neil, MD, and Rex W. Force, PharmD, BCPSRosiglitazone in the treatment of type 2 diabetes mellitus: a critical reviewThiazolidinediones: A Comparative Review of Approved UsesRosiglitazone and Liver FailureWilliam L. Isley, MD and Julie C. Oki, PharmDRosiglitazone and Liver FailureLisa M. Forman, MD and Robert H. Diamond, MDDRUG-INDUCED LIVER DISEASEEfficacy and Safety of Troglitazone in the Treatment of Lipodystrophy SyndromesElif Arioglu, MD, Jennifer Duncan-Morin, RN, Nancy Sebring, RD, Kristina I. Rother, MD, Nicole Gottlieb, BA, Jay Lieberman, BS, David Herion, MD, David E. Kleiner, MD, PhD, James Reynolds, MD, Ahalya Premkumar, MD, Anne E. Sumner, MD, Jay Hoofnagle, MD, Marc L. Reitman, MD, PhD, and Simeon I. Taylor, MD, PhDManagement of Type 2 Diabetes in the Geriatric PatientCurrent AwarenessThiazolidinediones: an update 18 January 2000Volume 132, Issue 2Page: 164KeywordsDrugsHypoxiaIntensive care unitsIschemiaLiverLiver diseasesSafetySerum glutamic oxaloacetic transaminaseVascular diseasesVascular surgery ePublished: 15 August 2000 Issue Published: 18 January 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...